Novartis has won a temporary reprieve from generic competition to its big-selling oral multiple sclerosis therapy Gilenya in the US, which accounts for around half its sales. The Swiss pharma group ...

The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market. A pharma company’s core mission is to improve patient outcomes. This ...

Nearly every SaaS product is either integrating AI or planning to do so. However, the term “AI” has become so broad that it’s ...